DashboardPortfoliosWatchlistCommunityDiscoverScreener
  • Community
  • /
  • Belgium
  • /
  • Healthcare
Author Program NEWCreate Narrative
FAGR logo

Fagron NV Stock Price

ENXTBR:FAGR Community·€1.5b Market Cap
  • 1 Narratives written by author
  • 0 Comments on narratives written by author
  • 18 Fair Values set on narratives written by author
Author Program NEWCreate Narrative

FAGR Share Price Performance

€21.10
0.20 (0.96%)
​
€28.25
Fair Value
€21.10
0.20 (0.96%)
25.3% undervalued intrinsic discount
€28.25
Fair Value
Price €21.10
AnalystConsensusTarget €28.25
Wed, 24 Jun 26
Fair Value€28.25
Share Pricen/a

FAGR Community Narratives

AN
AnalystConsensusTarget
AnalystConsensusTarget's
Fair Value
·
Fair Value €28.25 25.3% undervalued intrinsic discount

APAC Expansion And Compounding Services Will Unlock Future Value

0users have liked this narrative
0users have commented on this narrative
10users have followed this narrative
FAGR logo
Fagron
25.3% undervalued intrinsic discount

APAC Expansion And Compounding Services Will Unlock Future Value

View narrative
AN
AnalystConsensusTarget
AnalystConsensusTarget
Updated 24 Jun
Read Narrative

Trending Discussion

No trending discussion available.

Recently Updated Narratives

AN
AnalystConsensusTarget
FAGR logo

FAGR: Dividend Payout And Acquisition Discipline Will Support Future Upside

Fair Value: €28.25 25.3% undervalued intrinsic discount
10 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative

Snowflake Analysis

Good value with adequate balance sheet.

1 Risk
4 Rewards
View Full Analysis

Fagron NV Key Details

€1.0b

Revenue

€571.9m

Cost of Revenue

€456.6m

Gross Profit

€364.9m

Other Expenses

€91.7m

Earnings

Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
Feb 11, 2027
1.25
44.40%
8.92%
95.7%
View Full Analysis

About FAGR

Founded
1990
Employees
4880
CEO
Rafael Padilla
WebsiteView website
www.fagron.com

Fagron NV, a pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, patients, and worldwide. It operates through three segments: Essentials, Brands, and Compounding Services. The company's products include DiluCap, a line of excipients to compound every capsule formulation; DiluTab, for Cardiology and Primary care application; Imuno TF Complex helps in regulation of immune responses; Pigmerise, a natural phytocomplex for hypopigmentation disorders, such as vitiligo; Pentravan uses for avoiding first-pass metabolism and preventing gastrointestinal erosion; Nourisil MD, a first line therapy for prevention and treatment of scars ang keloids; Neogen, a line of hair care products; TrichoConcept used to treat alopecia; Fagron Advanced Derma for basic skincare, compound pharmaceutical treatment, and individualized dermatological care; SyrSpend SF that provides pharmaceutical stability, dosage consistency, and patient comfort; and Cleoderm, a topical cream used for the compounding of personalized dermatological treatments. It also offers education and professional development of prescribers, hospitals, and pharmacists through the Fagron Academy. The company was formerly known as Arseus NV and changed its name to Fagron NV in January 2015. Fagron NV was founded in 1990 and is based in Nazareth, Belgium.

Recent FAGR News & Updates

Recent updates

No updates

Fagron NV Competitors

IBAB logo

Ion Beam Applications

Symbol: ENXTBR:IBAB
Market cap: €443.3m
ONWD logo

Onward Medical

Symbol: ENXTBR:ONWD
Market cap: €185.3m
View more competitors

Make Better Investing Decisions Anywhere

Scan to download
Open AppStoreOpen Google Play
Chrome Web Store
Level 5, 320 Pitt Street, Sydney
Financial Data provided by S&P Global Market Intelligence LLC, analysis provided by Simply Wall Street Pty Ltd. Copyright © 2026, S&P Global Market Intelligence LLC. All rights reserved.
View Data Sources
Markets
  • US: NYSE & NASDAQ
  • UK: FTSE
  • Australia: ASX
  • India: NIFTY
  • Canada: TSX
  • South Africa: JSE
  • Japan: NIKKEI
  • South Korea: KOSPI
  • Germany: DAX
Investing Ideas
  • Undervalued Companies
  • Dividend Powerhouses
  • Insider Buying
  • Nuclear Energy
  • Autonomous Vehicles
  • Artificial Intelligence
  • Crypto and Blockchain
  • Cybersecurity
  • More ideas
Stock Communities
  • AstraZeneca
  • HSBC Holdings
  • Shell
  • Unilever
  • Diageo
  • Rio Tinto Group
  • RELX
  • BP
  • Barclays
Features & Tools
  • Portfolio Tracker
  • Stock Screener & Alerts
  • Narratives & Fair Values
  • Dividend Calculator
News & Discovery
  • Latest Stock News
  • Global Market Insights
  • The Foxhole
  • Investing Ideas
  • Community Narratives
  • What's New
Simply Wall St
  • Plans & Pricing
  • Advertising
  • About Us
  • Contact Us
  • Careers
  • Help Center
  • Learn Stock Investing
  • Affiliate Program
  • Business & Enterprise
  • Charlie AI
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
© 2026 Simply Wall Street Pty Ltd, US Design Patent #29/544/281, Community and European Design Registration #2845206
  • Terms and Conditions
  • Privacy Policy
  • AI Terms
  • Financial Services Guide